These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30244398)

  • 1. Anti-tumor necrosis factor therapy decreases the risk of initial intestinal surgery after diagnosis of Crohn's disease of inflammatory type.
    Nagata Y; Esaki M; Moriyama T; Hirano A; Umeno J; Maehata Y; Torisu T; Matsumoto T; Kitazono T
    J Gastroenterol; 2019 Apr; 54(4):330-338. PubMed ID: 30244398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease.
    Safroneeva E; Vavricka SR; Fournier N; Pittet V; Peyrin-Biroulet L; Straumann A; Rogler G; Schoepfer AM;
    Aliment Pharmacol Ther; 2015 Oct; 42(8):977-89. PubMed ID: 26271358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.
    Yamada A; Komaki Y; Patel N; Komaki F; Pekow J; Dalal S; Cohen RD; Cannon L; Umanskiy K; Smith R; Hurst R; Hyman N; Rubin DT; Sakuraba A
    Inflamm Bowel Dis; 2018 Feb; 24(3):502-509. PubMed ID: 29462385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study.
    González-Lama Y; Suárez C; González-Partida I; Calvo M; Matallana V; de la Revilla J; Magaz M; Bernardo C; Agudo B; Ibarrola P; Relea L; Arévalo J; Vera MI; Abreu L
    J Crohns Colitis; 2016 Jan; 10(1):55-60. PubMed ID: 26520164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examination Under Anesthesia May Not Be Universally Required Prior to Anti-TNF Therapy in Perianal Crohn's Disease: A Comparative Cohort Study.
    Chan M; Fung M; Chin Koon Siw K; Khanna R; de Buck van Overstraeten A; Sabri E; McCurdy JD
    Inflamm Bowel Dis; 2023 May; 29(5):763-770. PubMed ID: 35815783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors.
    Oh EH; Oh K; Han M; Seo H; Chang K; Lee SH; Kim GU; Song EM; Seo M; Lee HS; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
    PLoS One; 2017; 12(5):e0177479. PubMed ID: 28542298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all.
    Melmed GY; Spiegel BM; Bressler B; Cheifetz AS; Devlin SM; Harrell LE; Irving PM; Jones J; Kaplan GG; Kozuch PL; Velayos FS; Baidoo L; Sparrow MP; Siegel CA
    Clin Gastroenterol Hepatol; 2010 Aug; 8(8):655-9. PubMed ID: 20451665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease.
    Osterman MT; Haynes K; Delzell E; Zhang J; Bewtra M; Brensinger CM; Chen L; Xie F; Curtis JR; Lewis JD
    Clin Gastroenterol Hepatol; 2015 Jul; 13(7):1293-1301.e5; quiz e70, e72. PubMed ID: 25724699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Influence of Preoperative Medications on Postoperative Complications in Patients After Intestinal Surgery for Crohn's Disease.
    Yu CS; Jung SW; Lee JL; Lim SB; Park IJ; Yoon YS; Kim CW; Yang SK; Ye BD; Park SH; Han M; Kim JC
    Inflamm Bowel Dis; 2019 Aug; 25(9):1559-1568. PubMed ID: 30753560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Ileocecal Resection for Crohn's Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study.
    Agrawal M; Ebert AC; Poulsen G; Ungaro RC; Faye AS; Jess T; Colombel JF; Allin KH
    Gastroenterology; 2023 Oct; 165(4):976-985.e3. PubMed ID: 37321356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to Optimize Anti-tumor Necrosis Factor Therapy for Perianal Fistulizing Crohn's Disease: A Systematic Review.
    Tandon P; Rhee GG; Schwartz D; McCurdy JD
    Dig Dis Sci; 2019 Nov; 64(11):3066-3077. PubMed ID: 31030304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of medical therapy on patients with Crohn's disease requiring surgical resection.
    Fu YT; Hong T; Round A; Bressler B
    World J Gastroenterol; 2014 Sep; 20(33):11808-14. PubMed ID: 25206286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-α Therapy in a Paediatric Crohn's Disease Cohort.
    Nuti F; Civitelli F; Bloise S; Oliva S; Aloi M; Latorre G; Viola F; Cucchiara S
    J Crohns Colitis; 2016 Jan; 10(1):5-12. PubMed ID: 26188350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinctive histopathologic phenotype in resection specimens from patients with Crohn's disease receiving anti-TNF-α therapy.
    Schaeffer DF; Walsh JC; Kirsch R; Waterman M; Silverberg MS; Riddell RH
    Hum Pathol; 2014 Sep; 45(9):1928-35. PubMed ID: 25022570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn's disease.
    Vuyyuru SK; Kante B; Kumar P; Sahu P; Kedia S; Ranjan MK; Sharma R; Panwar R; Makharia G; Ahuja V
    Sci Rep; 2021 Jun; 11(1):11704. PubMed ID: 34083575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory Cytokine Profile in Crohn's Disease Nonresponders to Optimal Antitumor Necrosis Factor Therapy.
    Yarur AJ; Jain A; Quintero MA; Czul F; Deshpande AR; Kerman DH; Abreu MT
    J Clin Gastroenterol; 2019 Mar; 53(3):210-215. PubMed ID: 29517712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis.
    Targownik LE; Tennakoon A; Leung S; Lix LM; Singh H; Bernstein CN
    Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1061-1070.e1. PubMed ID: 28238957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rate of Reoperation Decreased Significantly After Year 2002 in Patients With Crohn's Disease.
    Shinagawa T; Hata K; Ikeuchi H; Fukushima K; Futami K; Sugita A; Uchino M; Watanabe K; Higashi D; Kimura H; Araki T; Mizushima T; Itabashi M; Ueda T; Koganei K; Oba K; Ishihara S; Suzuki Y
    Clin Gastroenterol Hepatol; 2020 Apr; 18(4):898-907.e5. PubMed ID: 31336198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables.
    Siegel CA; Horton H; Siegel LS; Thompson KD; Mackenzie T; Stewart SK; Rice PW; Stempak JM; Dezfoli S; Haritunians T; Levy A; Baek M; Milgrom R; Dulai PS; Targan SR; Silverberg MS; Dubinsky MC; McGovern DP
    Aliment Pharmacol Ther; 2016 Jan; 43(2):262-71. PubMed ID: 26567467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.